CytoMed Therapeutics Limited - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
GDTC Nasdaq 2830 w2.cytomed.sg

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for CytoMed Therapeutics Limited

CytoMed Therapeutics And 2 More Penny Stocks With Promising Prospects - Feb 6th, 2026 11:05 am
Cytomed Therapeutics refutes ‘misleading’ claims, reaffirms clinical progress - Jan 29th, 2026 8:11 am
CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress - Jan 28th, 2026 8:00 am
CytoMed Therapeutics’ new year update and seeks shareholders’ feedback on proposal to improve shareholder value for their patient capital - Jan 13th, 2026 6:00 am
CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Cells Allogeneic Technology to Treat Cancers in Malaysia - Dec 8th, 2025 6:00 am
CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and India - Nov 18th, 2025 6:00 am
CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China Strategy - Nov 6th, 2025 6:00 am
CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95% - Oct 22nd, 2025 6:00 am
CytoMed makes cash bid for potential acquisition of TC BioPharm Limited’s relevant assets - Oct 14th, 2025 6:00 am
CytoMed Therapeutics Announces Publication of Collaborative Research with The University of Texas, MD Anderson Cancer Center, Demonstrating the Potential of Allogeneic γδ T Cells in Acute Myeloid Leukemia - Oct 2nd, 2025 5:00 am
Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition - Aug 28th, 2025 7:00 am
CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program - Aug 18th, 2025 7:00 pm
Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies - Jul 21st, 2025 8:01 am